Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

David Wallace

Executive Editor

Birmingham, UK

Having previously worked in the European chemicals industry, Dave has been with Generics Bulletin since 2010. Keeping a close eye on deals, corporate strategy and market developments in the off-patent sector, he also brings his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, with a particular interest in France where he has lived and studied in the past. A regular delegate to generics and biosimilars events and conferences as well as a frequent panel moderator, he maintains close links with industry representatives around the world. He also organizes and judges the annual Global Generics & Biosimilars Awards. In his spare time, he enjoys art and playing the piano.

Latest From David Wallace

Stada Begins Work On Romanian Hub

Stada has begun work on a facility in Romania into which the German giant is investing more than €50m to bolster the European supply chain.

Manufacturing Strategy

Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected

Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.

Biosimilars Market Intelligence

Alvotech Switches CEO And Takes COO From Teva

Major leadership changes are being made at the top of Alvotech, with founder Robert Wessman stepping in to replace Mark Levick as CEO at the same time as Teva’s former head of global R&D, Hafrun Fridriksdottir, becomes COO of the biosimilars developer.

Executive Changes Leadership

Faster And Cheaper: Similis Bio Aims To Enhance Biosimilar Development

In the wake of Similis Bio’s first biosimilar partnership, the JSR Life Sciences unit’s head, John Gabrielson, talks to Generics Bulletin about the Similis Bio model and how the firm believes it can help bring biosimilars to market more rapidly and efficiently.

Biosimilars Deals

Teva Appoints Former Sandoz CEO Francis To Replace Schultz

Teva will soon have a new president and CEO with former Sandoz chief Richard Francis announced as Kåre Schultz’s replacement from the start of 2023.

Executive Changes Leadership

IHP’s ‘Big Give’ Will Double The Value Of Donations

UK-based charity International Health Partners is once again doubling the value of donations to its ‘Big Give’ appeal in early December, with this year’s total set to be donated to countries in the Horn of Africa where access to medicines is in jeopardy.

Market Access Generic Drugs
See All
UsernamePublicRestriction

Register